Intracellular Therapeutics Pipeline
Diverse and Expanding Pipeline of RNA-, Antibody- and Enzyme-Based Programs Spanning Discovery and Clinical Development
At Entrada Therapeutics, we are driven to transform the lives of patients by establishing a new class of intracellular therapeutics. We are already developing potential treatments across multiple devastating diseases with a simple and scalable EEV platform designed to translate from preclinical to clinical development.
Neuromuscular Disease
ENTR-601-44 (Exon 44 Skipping Oligonucleotide)
Duchenne Muscular Dystrophy
Discovery
100%
complete
Lead Optimization
100%
complete
IND Enabling
100%
complete
Clinical
10%
complete
ENTR-601-45 (Exon 45 Skipping Oligonucleotide)
Duchenne Muscular Dystrophy
Discovery
100%
complete
Lead Optimization
100%
complete
IND Enabling
75%
complete
Clinical
0%
complete
ENTR-601-50 (Exon 50 Skipping Oligonucleotide)
Duchenne Muscular Dystrophy
Discovery
100%
complete
Lead Optimization
100%
complete
IND Enabling
25%
complete
Clinical
0%
complete
Exon 51 (Exon 51 Skipping Oligonucleotide)
Duchenne Muscular Dystrophy
Discovery
100%
complete
Lead Optimization
50%
complete
IND Enabling
0%
complete
Clinical
0%
complete
VX-670 (Oligonucleotide) 1
Myotonic Dystrophy Type 1
Discovery
100%
complete
Lead Optimization
100%
complete
IND Enabling
100%
complete
Clinical
10%
complete
ERT/Oligonucleotide
Pompe
Discovery
100%
complete
Lead Optimization
20%
complete
IND Enabling
0%
complete
Clinical
0%
complete
Beyond Neuromuscular
Immunology
Discovery
100%
complete
Lead Optimization
0%
complete
IND Enabling
0%
complete
Clinical
0%
complete
Ocular
Discovery
100%
complete
Lead Optimization
50%
complete
IND Enabling
0%
complete
Clinical
0%
complete
Platform Expansion
Gene Editing
Discovery
80%
complete
Lead Optimization
0%
complete
IND Enabling
0%
complete
Clinical
0%
complete
mRNA Delivery
Discovery
80%
complete
Lead Optimization
0%
complete
IND Enabling
0%
complete
Clinical
0%
complete
Antibody/Protein
Discovery
80%
complete
Lead Optimization
0%
complete
IND Enabling
0%
complete
Clinical
0%
complete
References
-
1.
In collaboration with
